PMID- 21711060
OWN - NLM
STAT- MEDLINE
DCOM- 20111011
LR  - 20211020
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 71
IP  - 9
DP  - 2011 Jun 18
TI  - Tuberculosis and HIV co-infection: screening and treatment strategies.
PG  - 1133-52
LID - 10.2165/11591360-000000000-00000 [doi]
AB  - Globally, tuberculosis (TB) and HIV interact in deadly synergy. The high burden 
      of TB among HIV-infected individuals underlies the importance of TB diagnosis, 
      treatment and prevention for clinicians involved in HIV care. Despite expanding 
      access to antiretroviral therapy (ART) to treat HIV infection in resource-limited 
      settings, many individuals in need of therapy initiate ART too late and have 
      already developed clinically significant TB by the time they present for care. 
      Many co-infected individuals are in need of concurrent ART and anti-TB therapy, 
      which dramatically improves survival, but also raises several management 
      challenges, including drug interactions, shared drug toxicities and TB immune 
      reconstitution inflammatory syndrome (IRIS). Due to the survival benefits of 
      promptly initiating ART among all HIV-infected individuals, including those with 
      TB, it is recommended that co-infected individuals receive treatment for both 
      diseases, regardless of CD4+ cell count. We review current screening and 
      treatment strategies for TB and HIV co-infection. Recent findings and ongoing 
      studies will assist clinicians in managing the prevention and treatment of TB and 
      HIV co-infection, which remains a major global health challenge.
FAU - Venkatesh, Kartik K
AU  - Venkatesh KK
AD  - Division of Infectious Diseases, Department of Medicine, Alpert Medical School, 
      Brown University/Miriam Hospital, Providence, RI, USA.
FAU - Swaminathan, Soumya
AU  - Swaminathan S
FAU - Andrews, Jason R
AU  - Andrews JR
FAU - Mayer, Kenneth H
AU  - Mayer KH
LA  - eng
GR  - D43TW000237/TW/FIC NIH HHS/United States
GR  - F30 MH079738-01A2/MH/NIMH NIH HHS/United States
GR  - P30 AI42853/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - AIDS-Related Opportunistic Infections/diagnosis/drug therapy/etiology
MH  - Anti-HIV Agents/adverse effects/therapeutic use
MH  - Antitubercular Agents/adverse effects/therapeutic use
MH  - Drug Interactions
MH  - HIV Infections/complications/*drug therapy/epidemiology
MH  - Humans
MH  - Mass Screening/*methods
MH  - Medication Adherence
MH  - Tuberculosis/diagnosis/*drug therapy/etiology
EDAT- 2011/06/30 06:00
MHDA- 2011/10/12 06:00
CRDT- 2011/06/30 06:00
PHST- 2011/06/30 06:00 [entrez]
PHST- 2011/06/30 06:00 [pubmed]
PHST- 2011/10/12 06:00 [medline]
AID - 3 [pii]
AID - 10.2165/11591360-000000000-00000 [doi]
PST - ppublish
SO  - Drugs. 2011 Jun 18;71(9):1133-52. doi: 10.2165/11591360-000000000-00000.